On November 10, 2021 IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, reported that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 17, 2021 at 1:40 p.m. GMT/ 8:40 a.m. EST (Press release, IGM Biosciences, NOV 10, 2021, View Source [SID1234595229]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

On November 10, 2021 Vyant Bio, Inc. ("Vyant Bio", "Company") (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases (Press release, Vyant Bio, NOV 10, 2021, View Source [SID1234595280]). Today, Vyant Bio reported that it will be presenting at the Q4 Investor Summit Micro & Small Cap Conference ("Q4 Investor Summit"). The event is being held virtually from November 16-17, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Date: November 16-17, 2021 (Tuesday-Wednesday)
Presentation Time: 11:45am – 12:15pm ET – Wednesday, November 17, 2021
Presentation Link: View Source
1:1 Availability: 8am – 4:45pm ET daily
Event Registration: View Source
During the presentation, Vyant Bio’s Chief Executive Officer, Jay Roberts, will highlight the Company’s addition of its Chief Scientific Officer, progress being made with its drug discovery programs, noteworthy collaborations and partnerships, and the broader going-forward corporate strategy.

The presentation will be webcast and an archived recording will be made available in the Investors’ section of the Vyant Bio website and also on the Q4 Investor Summit website for 90 days following the event.

If you are an investor and would like to attend the Q4 Investor Summit, please click on the following link (View Source) to register. Once your registration is confirmed, you will be prompted to log into the conference website and will be able to request a one-on-one meeting with the Company.

Vyant Bio will also be available for virtual outside 1:1 meetings both during and after the Q4 Investor Summit Micro & Small Cap Conference. Please contact Jennifer K. Zimmons, PhD at [email protected] or +1 917.214.3514 for scheduling.

On November 10, 2021 SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, reported third quarter 2021 financial results and recent portfolio updates (Press release, SQZ Biotech, NOV 10, 2021, View Source [SID1234595296]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This was another period of strong execution where we have continued to meaningfully advance our cell therapy platforms and clinical programs. We were pleased with the recent DSMB recommendation to advance our highest APC dose into combination with checkpoint inhibitors for patients with HPV16 positive cancers," said Armon Sharei, Ph.D., Chief Executive Officer at SQZ Biotechnologies. "We were also excited to announce that celiac disease will be the first autoimmune disease target for our TAC platform, with an IND submission projected for next year. These activities highlight our deep commitment to driving patient impact across disease areas through the implementation of innovative cell therapies."

Third Quarter 2021 and Recent Business and Portfolio Updates

SQZ Antigen Presenting Cell ("APC") Platform in Oncology

Independent Data and Safety Monitoring Board (DSMB) recommends that the Phase 1/2 clinical trial SQZ-PBMC-HPV-101 advance into the combination stage with checkpoint inhibitors
DSMB recommendation and initiation of the combination cohorts trigger Roche collaboration agreement milestone payment
Oral presentation on highest-dose cohort of SQZ-PBMC-HPV-101 trial announced for the ESMO (Free ESMO Whitepaper) Immuno-Oncology Congress, December 9, 2021 in Geneva, Switzerland
SQZ Enhanced Antigen Presenting Cell ("eAPC") Platform in Oncology

New eAPC preclinical data to be presented on November 12, 2021 at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Congress demonstrates delivery of multiple mRNA to engineer APC function
Anticipate IND submission for the first clinical candidate by year-end 2021
SQZ Activating Antigen Carriers ("AAC") Platform in Oncology

New AAC preclinical data to be presented at SITC (Free SITC Whitepaper) highlights the potential combination therapy impact of SQZ AACs with a chemotherapy agent often used in early-line treatment of HPV16+ cancers
SQZ Tolerizing Antigen Carriers ("TAC") Platform in Immune Tolerance

Announced Q3 2022 IND submission target for celiac disease as the first clinical translation of the company’s TAC platform in autoimmune diseases
SQZ Potential Pipeline Expansion Research

Presenting first enhanced tumor infiltrating lymphocyte (TIL) preclinical data at SITC (Free SITC Whitepaper) showing the development of mRNA modified TILs with enhanced functionality in the absence of exogenous IL-2 cytokine support
Third Quarter 2021 Financial Highlights

Revenue for the third quarter 2021 was $4.8 million, compared to $6.1 million for the same period last year
Net loss for the third quarter 2021 was $22.5 million, compared to $12.4 million for the same period last year
Research and development expenses for the third quarter 2021 were $20.5 million, compared to $13.9 million for the same period last year. The increase was primarily attributable to planned development and manufacturing costs related to the eAPC platform
General and administrative expenses for the third quarter 2021 were $6.7 million, compared to $4.6 million for the same period last year. The increase was primarily due to higher personnel and other corporate-related costs, including stock-based compensation expense and other costs related to operating as a public company
As of September 30, 2021, the company had cash and cash equivalents of $164.3 million and anticipates this will be sufficient to fund operating expenses and capital expenditure requirements through the first half of 2023. This projected cash runway is inclusive of the anticipated Roche milestone payment associated with the advancement of the SQZ-PBMC-HPV-101 Phase 1/2 study

On November 10, 2021 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, reported that it will take part in two fireside chats, the first at the Stifel Healthcare Conference 2021, November 15-17, and the second at the Jefferies London Healthcare Conference, November 16-19. Both conferences will be held virtually (Press release, Cue Biopharma, NOV 10, 2021, View Source [SID1234608268]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the fireside chats, Cue Biopharma will provide an updated corporate overview and recent data highlighting its lead clinical program, CUE-101, representative of the IL-2 based CUE-100 series, as a monotherapy and in combination with KEYRUDA (pembrolizumab) for the treatment of patients with HPV+ recurrent/metastatic head and neck cancer. The discussion will also focus on the Company’s CUE-100 series pipeline progress with drug product candidates CUE-102, targeting Wilms’ Tumor 1 (WT1) and CUE-103, targeting KRAS G12V, as well as its most recent Neo-STAT platform developments.

Presentation Details:

Stifel Healthcare Conference
Date and Time: Monday, November 15, 2:40 p.m. – 3:10 p.m. EST
Webcast link: View Source

A live and archived webcast of the fireside chat will be available on the Events page in the Investor and Media section of the Company’s website at www.cuebiopharma.com. The webcast will be archived for 30 days.

Jefferies Virtual London Healthcare Conference
Date and Time: The pre-recorded fireside chat will be available to conference attendees on-demand between 8:00 a.m. GMT/3:00 a.m. EST on Thursday, November 18 through 5:00 p.m. GMT/12:00 p.m. on Friday, November 19.

A replay of the fireside chat will be hosted on the conference website and available to attendees for 30 days after the event. For more information, email [email protected].

Also, an archived webcast of the fireside chat will be available after the conference on the Events page in the Investor and Media section of the Company’s website at www.cuebiopharma.com. The webcast will be archived for 30 days.

On November 10, 2021 Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809, NASDAQ: EVO) reported that the Company reached additional programme designations within its neuroscience collaboration with Bristol Myers Squibb (NYSE:BMY) triggering payments of in total US$ 40 m to Evotec (Press release, Evotec, NOV 10, 2021, View Source [SID1234594996]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These target-based programme designations further bolster the growing pipeline and are expected to follow EVT8683, which Bristol Myers Squibb opted to license after the successful filing of an IND application with the FDA.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, said: "Our collaboration with BMS continues to be highly productive. These achievements are a testimony of the great team spirit between Bristol Myers Squibb and Evotec colleagues that enabled us to advance highly challenging programmes to key value inflection points."

The collaboration was initiated in December 2016 with the goal of identifying disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of the patients’ symptoms and there is a huge unmet medical need for therapeutic modalities that slow down or reverse disease progression. The collaboration leverages Evotec’s industrialised iPSC platform using patient-derived disease models, which is one of the largest and most sophisticated platforms in the industry.